Sunesis Pharmaceuticals, Inc. (SNSS): Price and Financial Metrics


Sunesis Pharmaceuticals, Inc. (SNSS)

Today's Latest Price: $1.36 USD

0.09 (7.09%)

Updated Nov 24 4:00pm

Add SNSS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

SNSS Stock Summary

  • For SNSS, its debt to operating expenses ratio is greater than that reported by only 5.49% of US equities we're observing.
  • With a year-over-year growth in debt of -93.62%, Sunesis Pharmaceuticals Inc's debt growth rate surpasses merely 1.72% of about US stocks.
  • The volatility of Sunesis Pharmaceuticals Inc's share price is greater than that of 96.53% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sunesis Pharmaceuticals Inc are AKBA, VIE, ONCT, ADXS, and AVEO.
  • SNSS's SEC filings can be seen here. And to visit Sunesis Pharmaceuticals Inc's official web site, go to www.sunesis.com.

SNSS Stock Price Chart Interactive Chart >

Price chart for SNSS

SNSS Price/Volume Stats

Current price $1.36 52-week high $11.30
Prev. close $1.27 52-week low $1.12
Day low $1.26 Volume 904,100
Day high $1.38 Avg. volume 706,883
50-day MA $1.30 Dividend yield N/A
200-day MA $3.59 Market Cap 24.61M

Sunesis Pharmaceuticals, Inc. (SNSS) Company Bio


Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company was founded in 1998 and is based in South San Francisco, California.


SNSS Latest News Stream


Event/Time News Detail
Loading, please wait...

SNSS Latest Social Stream


Loading social stream, please wait...

View Full SNSS Social Stream

Latest SNSS News From Around the Web

Below are the latest news stories about Sunesis Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNSS as an investment opportunity.

The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ...

Benzinga | September 15, 2020

The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Akouos Inc (NASDAQ: AKUS ) Albireo Pharma Inc (NASDAQ: ALB )(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) Castle Biosciences Inc (NASDAQ: CSTL ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Kura Oncology Inc (NASDAQ: KURA ) Merit Medical Systems, Inc. (NASDAQ: MMSI )(announced sale of manufacturing equipment and associated assets used in its hypotube manufacturing business) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 8) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AEterna Zentaris Inc. (NASDAQ: AEZS )(announced the presentation of data from pediatric study of macimorelin for childhood-o...

Benzinga | September 9, 2020

The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...

Benzinga | September 4, 2020

The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp ...

Benzinga | September 3, 2020

Recap: Sunesis Pharmaceuticals Q2 Earnings

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) were down 4.45% in after-market trading after the company reported Q2 results. Quarterly Results Earnings …

Benzinga | August 11, 2020

Read More 'SNSS' Stories Here

SNSS Price Returns

1-mo -6.53%
3-mo -53.22%
6-mo -65.46%
1-year -68.52%
3-year -95.42%
5-year -97.56%
YTD -59.73%
2019 -18.82%
2018 -88.73%
2017 1.93%
2016 -32.96%
2015 -64.71%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7963 seconds.